<DOC>
	<DOCNO>NCT00774280</DOCNO>
	<brief_summary>1 . At time registration , patient randomize one two conditioning therapy group ; Arm I ( intravenous busulfan plus cyclophosphamide ; BuCy ) Arm II ( intravenous busulfan plus fludarabine ; BuFlu ) . 2 . Randomization stratify permuted-block design . 2.1The patient stratified standard risk vs. high risk group , relate vs. unrelated donor . Standard risk group define follow : patient acute leukemia first remission , CML chronic phase , MDS ( RA RARS category ) . High risk group define follow : patient acute leukemia relapse second subsequent remission , CML accelerate blastic phase , MDS ( CMMoL RAEB category ) . 2.2.Pre-assigned block size 8 .</brief_summary>
	<brief_title>Busulfan Plus Cyclophosphamide v Fludarabine Conditioning Regimen</brief_title>
	<detailed_description>1 . TREATMENT PLAN - The patient admit laminar air flow room . - The patient triple lumen Hickman central venous catheter ( CVC ) place . Vancomycin 1 gm IV immediately prior CVC placement 1 gm q 12 hour 3 dos . Chest X-ray take CVC placement confirm location CVC absence pneumothorax . - Lumbar puncture do intrathecal preservative free methotrexate 10 ㎎/㎡ ( exceed 12 ㎎ total ) give . Folinic acid 15 ㎎ give po IV 24 hour intrathecal methotrexate q 6 hour total 4 dos . - Menstruating woman give norethindrone ( Norlutate ) 10 ㎎ po daily . 2 . The preparatory regimen follow : - Conditioning therapy start day -7 patient randomized receive intravenous busulfan ( Busulfex® ; Orphan Medical , Minnetonka , MN ) plus cyclophosphamide . Busulfex 3.2 ㎎/㎏ administer daily 4 day ( day -7 -4 ) follow cyclophosphamide 60 ㎎/㎏ D5W 200 ㎖ i.v . 1-2 hour day -3 -2 . Busulfex dilute normal saline 500 ㎖ infuse 3 hour pump central venous catheter The dos Busulfex cyclophosphamide calculate use follow guideline : 1 ) actual body weight ( ABW ) patient le equal ideal body weight ( IBW ) , ABW use . 2 ) ABW great IBW less 20 % , IBW use . 3 ) ABW great IBW equal 20 % , dose base ; IBW + 25 % ( ABW-IBW ) . IBW calculate follow : 50 ㎏ + 2.3 ㎏ ( Height inch - 60 ) male , 45.5 ㎏ +2.3 ㎏ ( Height inch -60 ) ( 1 inch= 2.54 ㎝ ) . - Conditioning therapy start day -7 patient randomized receive Busulfex plus fludarabine ( Fludara® , Schering AG , Berlin , Germany ) . Busulfex 3.2 ㎎/㎏ administer daily 4 day ( day -7 -4 ) fludarabine 30 ㎎/㎡ infuse intravenously 30 minute D5W 100 ㎖ 5 consecutive day ( day -6 -2 ) . The dose Busulfex calculate use above-mentioned guideline ( see 5.5.1 ) . The dose fludarabine calculate use ABW . 3 . GVHD prophylaxis - All patient receive cyclosporine 1.5 ㎎/㎏ NS 100 ㎖ i.v . 2-4 hour q 12 hr ( dose cyclosporine round near 5 ㎎ ) start day -1 9 a.m. Cyclosporine dose adjust provide appropriate level accord change renal function ( see Appendix II ) . - When patient tolerate oral medication , cyclosporine give p.o . 3 ㎎/㎏ ( two time i.v . dose ) q 12 hr . - Cyclosporine dose decrease 10 % every month start day 60 BMT provide clinical evidence GVHD . - In addition cyclosporine , methotrexate 15 ㎎/㎡ give intravenously day 1 10 ㎎/㎡ day 3 , 6 , 11 . The dose methotrexate decrease omit accord guideline provide Appendix III . - Methotrexate give patient acute leukemia MDS receive hematopoietic cell graft HLA-matched sibling donor 4 . Bone marrow cell infusion - For ABO match minor mismatch transplantation , premedication Avil 45.5mg I.v . push tylenol 600 ㎎ p.o . give . Stem cell infuse 1-2 hr . - For major ABO mismatch transplantation , premedication Avil 45.5 ㎎ i.v . push , tylenol 600 ㎎ p.o. , 10 % mannitol 100 g i.v . 4 hr start 30 min stem cell infusion , hydrocortisone 250 ㎎ i.v . give immediately 30 min stem cell infusion . 5 . Supportive care . - Dilantin 15 ㎎/㎏ ( ABW ) NS 200 ㎖ i.v . 1 hour load day -8 , 200 ㎎ p.o . bid day -5 . Dilantin dose adjust provide therapeutic level . - Allopurinol 300 ㎎/day p.o . qd day -8 -2 . - Nystatin powder groin , axilla , perianal area bid day -8 absolute neutrophil count ( ANC ) &gt; 3,000/㎕ . - Sodium bicarbonate/saline mouthwash qid mucositis resolve . - Fluconazole 100 ㎎/day p.o . qd ANC &gt; 3,000/㎕ . - Ciprofloxacin 500 ㎎ p.o . bid ( selective bowel decontamination ) ANC &gt; 3,000/㎕ . With first fever spike , ciprofloxacin discontinue broad spectrum antibiotic begin . - Hydration do 0.9 % NS 100 ㎖/hour patient receive busulfan . - IV Immunoglobulin 500 ㎎/㎏ ( ABW ) i.v . 6 hour every week start day -7 day 120 , every month day 180 . - Prophylaxis Herpes simplex virus include acyclovir 250 ㎎/㎡ D5W 100 ㎖ i.v . q 8 hour start day -7 . When patient tolerate oral medication , acyclovir give 200 ㎎ p.o . tid day 180 . - Prophylaxis Pneumocystis carinii include Bactrim SS 2 tablet p.o . bid folinic acid 7.5 ㎎ p.o . bid , 2 day weekly , start engraftment day 360 . - Amoxacillin 250 ㎎ p.o . bid start day 70 day 360 . - G-CSF administration . - Starting day 5 , G-CSF 300 ㎍ 100 ㎖ D5W give i.v . 3 hour daily ANC &gt; 3,000/㎕ . - If ANC drop 1,000/㎕ , G-CSF administration resume continue ANC &gt; 3,000/㎕ . 6 . In patient acute leukemia CML blastic crisis , intrathecal methotrexate administration resume patient recovered platelet count 50,000/㎕ . Methotrexate 10 ㎎/㎡ ( exceed 12 ㎎ total ) give intrathecally every 2 week three time ( total four dos include one give preparatory regimen ) . Folinic acid 15 ㎎ give p.o . i.v . 24 hour intrathecal methotrexate q 6 hour total 4 dos .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients acute leukemia , chronic myelogenous leukemia , myelodysplastic syndrome , hematologic malignancy . Patients HLAidentical onelocus mismatch sibling , family unrelated donor . Patients 15 year age old , young 70 year . Patients major illness organ failure . Patients psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>